View More View Less
  • 1 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen, Nagyerdei krt. 98., 4032
  • 2 Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szeged
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Absztrakt:

Tíz év telt el azóta, hogy 2007-ben megjelent a Dry Eye WorkShop (DEWS) Report, mely összefoglalta a száraz szemről a szakirodalomban akkor elérhető legfontosabb információkat. Azóta közlemények százai jelentek meg ebben a témakörben, és eljött az idő az újabb összegzésre. A Tear Film & Ocular Surface Society (TFOS) szervezésében 12 munkacsoport összegezte a száraz szemmel kapcsolatos régi és új adatokat: megszületett a DEWS II Report. Ebben a közleményben a szerzők összefoglalják azokat a legfontosabb változásokat, amelyek a definíciótól a felosztáson és a diagnosztikán át a terápiáig a száraz szem vonatkozásában megváltoztak, és amelyekről a nem szemészként, más szakterületen dolgozó specialistáknak tájékozódni érdemes. A TFOS által közzétett DEWS II Report 11 alfejezetből áll. Teljesen új fejezetek szólnak az érzékelés/fájdalom szerepéről és a iatrogén száraz szemről. Orv Hetil. 2018; 159(20): 775–785.

  • 1

    TFOS DEWS II Report. Tear Film & Ocular Surface Work Shop II. Report. Ocul Surf. 2017; 15: 269–649.

  • 2

    Lemp MA. Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes. Contact Lens Assoc Ophthalmol J. 1995; 21: 221–232.

  • 3

    TFOS DEWS Report. 2007 Report of the International Dry Eye WorkShop (DEWS). Ocul Surf. 2007; 5: 65–204.

  • 4

    The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007; 5: 75–92.

  • 5

    Bron AJ, de Pavia CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017; 15: 438–510.

  • 6

    Chotikavanich S, de Paiva CS, Li de Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009; 50: 3203–3209.

  • 7

    Barabino S, Chen Y, Chauhan S, et al. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res. 2012; 31: 271–285.

  • 8

    Argueso P, Balaram M, Spurr-Michaud S, et al. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest Ophthalmol Vis Sci. 2002; 43: 1004–1011.

  • 9

    Morrison M, Allen PZ. Lactoperoxidase: identification and isolation from Harderian and lacrimal glands. Science 1966; 152: 1626–1628.

  • 10

    Alexander JH, Young JA, van Lennep EW. The ultrastructure of the duct system in the rat extraorbital lacrimal gland. Z Zellforsch Mikrosk Anat. 1973; 144: 453–466.

  • 11

    Chung CW, Tigges M, Stone RA. Peptidergic innervation of the primate meibomian gland. Invest Ophthalmol Vis Sci. 1996; 37: 238–245.

  • 12

    Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004; 137: 337–342.

  • 13

    Lam H, Bleiden L, de Paiva CS, et al. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol. 2009; 147: 198–205.

  • 14

    Belmonte C, Acosta MC, Merayo-Lloves J, et al. What causes eye pain? Curr Ophthalmol Rep. 2015; 3: 111–121.

  • 15

    Sullivan B. Challenges in using signs and symptoms to evaluate new bio-markers of dry eye disease. Ocul Surf. 2014; 12: 2–9.

  • 16

    Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003; 136: 318–326.

  • 17

    Schaumberg DA, Dana R, Buring JE, et al. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Arch Ophthalmol. 2009; 127: 763–768.

  • 18

    Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997; 124: 723–728.

  • 19

    Sullivan DA, Hann LE. Hormonal influence on the secretory immune system of the eye: endocrine impact on the lacrimal gland accumulation and secretion of IgA and IgG. J Steroid Biochem. 1989; 34: 253–262.

  • 20

    Schaumberg DA, Nichols JJ, Papas EB, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011; 52: 1994–2005.

  • 21

    Sullivan DA, Krenzer KL, Sullivan BD, et al. Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency? Invest Ophthalmol Vis Sci. 1999; 40: 1261–1265.

  • 22

    Thody AJ, Shuster S. Control and function of sebaceous glands. Physiol Rev. 1989; 69: 383–416.

  • 23

    Obata H, Yamamoto S, Horiuchi H, et al. Histopathologic study of human lacrimal gland. Statistical analysis with special reference to aging. Ophthalmology 1995; 102: 678–686.

  • 24

    Leach NE, Wallis NE, Lothringer LL, et al. Corneal hydration changes during the normal menstrual cycle – a preliminary study. J Reprod Med. 1971; 6: 201–204.

  • 25

    Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol. 2008; 8: 737–744.

  • 26

    Vachon G. Iatrogenic disease. In: Mullner RM (ed.) Encyclopedia of Health Services Research. SAGE Publications Inc., Thousand Oaks, CA, 2009; pp. 623–625.

  • 27

    Fraunfelder FT, Sciubba JJ, Mathers WD. The role of medications in causing dry eye. J Ophthalmol. 2012; 2012: 285851.

  • 28

    Franunfelder F, Fraunfelder FW, Chambers WA. Clinical ocular toxicology. Drugs, Chemicals and Herbs. Elsevier Saunders, Philadelphia, PA, 2008.

  • 29

    Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007; 17: 341–349.

  • 30

    Benito A, Pérez GM, Mirabet S, et al. Objective optical assessment of tear-film quality dynamics in normal and mildly symptomatic dry eyes. J Cataract Refrac Surg. 2011; 37: 1481–1487.

  • 31

    Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology Report. Ocul Surf. 2017; 15: 539–574.

  • 32

    Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007; 5: 108–152.

  • 33

    Li M, Gong L, Chapin WJ, et al. Assessment of vision-related quality of life in dry eye patients. Invest Ophthalmol Vis Sci. 2012; 53: 5722–5727.

  • 34

    Gumus K, Crockett CH, Rao K, et al. Noninvasive assessment of tear stability with the tear stability analysis system in tear dysfunction patients. Invest Ophthalmol Vis Sci. 2011; 52: 456–461.

  • 35

    Németh J, Erdélyi B, Csákány B, et al. High-speed videotopographic measurement of tear film build-up time. Invest Ophthalmol Vis Sci. 2002; 43: 1783–1790.

  • 36

    Potvin R, Makari S, Rapuano CJ. Tear film osmolarity and dry eye disease: a review of the literature. Clin Ophthalmol. 2015; 9: 2039–2047.

  • 37

    Szalai E, Berta A, Szekanecz Z, et al. Evaluation of tear osmolarity in non-Sjögren and Sjögren syndrome dry eye patients with the TearLab system. Cornea 2012; 31: 867–871.

  • 38

    Bron AJ, Argüeso P, Irkec M, et al. Clinical staining of the ocular surface: mechanisms and interpretations. Prog Retin Eye Res. 2015; 44: 36–61.

  • 39

    Bandlitz S, Purslow C, Murphy PJ, et al. Comparison of a new portable digital meniscometer and optical coherence tomography in tear meniscus radius measurement. Acta Ophthalmol. 2014; 92: 112–118.

  • 40

    Knop E, Knop N, Millar T, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011; 52: 1938–1978.

  • 41

    Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and therapy report. Ocul Surf. 2017; 15: 575–628.

  • 42

    Doughty MJ, Glavin S. Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review. Ophthalmic Physiol Opt. 2009; 29: 573–583.

  • 43

    Ziakas NG, Boboridis KG, Terzidou C, et al. Long-term follow up of autologous serum treatment for recurrent corneal erosions. Clin Exp Ophthalmol. 2010; 38: 683–687.

  • 44

    Hamano T. Lacrimal duct occlusion in the treatment of dry eye. Semin Ophthalmol. 2005; 20: 71–74.

  • 45

    Qin J, Zhang L, Cai ZG, et al. Microvascular autologous transplantation of partial submandibular gland for severe keratoconjunctivitis sicca. Br J Ophthalmol. 2013; 97: 1123–1128.

  • 46

    Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011; 52: 2050–2064.

  • 47

    Geerling G, Borrelli M. Adnexal surgery for severe ocular surface disease. Semin Ophthalmol. 2005; 20: 101–112.

  • 48

    Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004; 138: 444–457.

  • 49

    Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016; 26: 287–296.

  • 50

    Perez VL, Pflugfelder SC, Zhang S, et al. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016; 14: 207–215.